OTIVACTO Spain Non Interventional Study

Exclusion Criteria

• •1. Patients with contraindications according to Spiolto® Respimat® SmPC
• •2. Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 months
• •3. Patients continuing Long-acting beta2 agonist and inhalative corticosteroids (LABA-iCS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta2 agonists
• •4. Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks
• •5. Pregnancy and lactation
• •6. Patients currently listed for lung transplantation
• •7. Current participation in any clinical trial or any other non-interventional study of a drug or device